SCHEMBL2610330

SCHEMBL2610330

CC(=O)c1ccc2c(Cc3ccc(F)cc3)cn(C)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 2/20 0.43
TP53 P04637 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
HASPIN Q8TF76 3/20 0.41
SNCA P37840 1/20 0.41
MAOB P27338 2/20 0.41
ATM Q13315 1/20 0.39
POLB P06746 1/20 0.39
ALDH1A1 P00352 2/20 0.38
GAA P10253 1/20 0.38
PDPK1 O15530 1/20 0.38
CHEK2 O96017 1/20 0.38
ABL1 P00519 1/20 0.38
EGFR P00533 1/20 0.38
ERBB2 P04626 1/20 0.38
NTRK1 P04629 1/20 0.38
MET P08581 1/20 0.38
PDGFRB P09619 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2610331 0.90 MEN1 (0.47) KMT2AMEN1LMNATP53RXFP1
SCHEMBL2610255 0.87 LMNA (0.50) KMT2AMEN1LMNAHASPINPOLB
SCHEMBL2133199 0.86 KMT2A (0.47) KMT2AMEN1LMNATP53RXFP1
SCHEMBL913166 0.77 SLC22A12 (0.49) ALDH1A1GPR84
SCHEMBL121418 0.77 IDO1 (0.58) KMT2AMEN1ALDH1A1
SCHEMBL5458138 0.77 HASPIN (0.51) KMT2AMEN1LMNATP53RXFP1
SCHEMBL1992307 0.77 HASPIN (0.56) KMT2AMEN1LMNATP53RXFP1
SCHEMBL6840324 0.77 SNCA (0.50) HASPINSNCA
SCHEMBL21399652 0.74 HTR6 (0.40) KMT2AMEN1SNCAALDH1A1GPR84
SCHEMBL912699 0.73 IDH1 (0.45) LMNAGAAPDGFRBKDRGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748417-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2014-06-10 US disclosed
US-8575363-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2013-11-05 US disclosed
US-20130196970-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-08-01 US disclosed
US-20120101081-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196970-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, MGLL KMT2A 1314/4885MEN1 3469/4885LMNA 1887/4885
US-20120101081-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, MGLL KMT2A 1314/4885MEN1 3469/4885LMNA 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.